Nanjing Medical University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

5 drugs in development

Approved2

Phase 32

Phase 23

Phase 13

Preclinical3

By Therapeutic Area

top 6

Infectious Disease

421%

Cardiovascular

211%

Respiratory

211%

Neurology

211%

Gastroenterology

15%

Oncology

15%

R&D Momentum

57/100

Pipeline Velocity

25/100

Trial Completion Rate

100/100

Pipeline Concentration

14/100

Pipeline Freshness

29/100

Strategic Signals

↗Active in Cardiovascular but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 8, 2026

Recruiting

Using Single and Combined Nudge Strategies to Promote Healthier Beverage Intake Among College Students

Jul 7, 2026

Recruiting

Risk Trajectories and Prediction Model of Occupational Disidentification Among Undergraduate Nursing Interns: A Prospective Cohort Study

Earlier

Feb 1, 2026TrialVitamin B Supplementation for Patients Undergoing Cardiovascular Surgery

Jan 27, 2026TrialClinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus

Oct 15, 2025Trialγδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma

Apr 1, 2025TrialProtective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

Jan 1, 2025TrialProtective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery

Jan 1, 2025TrialProtective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)

4 more events

Jan 1, 2025TrialProtective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)

Jul 1, 2024TrialProtective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)

Jan 1, 2024TrialPrediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis (LVV) Based on PET/MRA Image Evaluation System

Jul 1, 2022TrialProtective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(2 drugs)

—

Cardiovascular(2 drugs)

Dermatology(1 drug)

—

Dermatology(1 drug)

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Infectious Disease(4 drugs)

—

Infectious Disease(4 drugs)

Metabolic & Endocrine(1 drug)

—

Metabolic & Endocrine(1 drug)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(2 drugs)

—

Neurology(2 drugs)

Oncology(1 drug)

—

Oncology(1 drug)

Respiratory(2 drugs)

—

Respiratory(2 drugs)

Unknown / Other(4 drugs)

—

Unknown / Other(4 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)